Tagged with “panitumumab”
ArchivesPreventive Measures Reduce Rash from Vectibix
Nearly all patients who are treated with Vectibix™ (panitumumab) will develop an itchy skin rash that looks something like acne. However, treating the rash preemptively before it appears reduces its severity and lengthens the time before more serious rash appears.
During the STEPP (Skin Toxicity Evaluation Protocol with Panitumumab) trial, researchers randomized patients who were being treated with Vectibix to either preemptive skin rash management at the beginning of chemotherapy or reactive treatment once rash appeared. After six weeks, 70 percent of patients treated preemptively had not developed grade 2 skin rash. Sixty-two percent of the reactive group already had rash that was grade 2 or higher. Continue reading…
Posted by Kate Murphy on June 27th, 2008
Posted in: Research & Treatment News | 7 Comments »
Tags: panitumumab, side effects, skin rash, Vectibix
